Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

Abstract Background Bladder cancer displays a broad mutational spectrum and intratumor heterogeneity (ITH), which results in difference in molecular phenotypes and resistance to therapies. However, there are currently no clinically available measures to predict patient prognosis using ITH. We aimed...

Full description

Bibliographic Details
Main Authors: Yuying Han, Xu Liu, Haihong Ye, Ye Tian, Zhengguo Ji
Format: Article
Language:English
Published: BMC 2020-11-01
Series:World Journal of Surgical Oncology
Subjects:
Mutant-allele tumor heterogeneity
FGFR3
Prognosis
Bladder cancer
Online Access:http://link.springer.com/article/10.1186/s12957-020-02084-3

Internet

http://link.springer.com/article/10.1186/s12957-020-02084-3

Similar Items